By Stephen Nakrosis
Shares of RAPT Therapeutics touched an all-time low following news the company terminated its zelnecirnon program after feedback from the Food and Drug Administration.
In the last hour of Monday's regular-trading session, the company's shares were trading 40% lower, at $1.70. Volume at the time topped 6.3 million shares, above the 65-day average volume of 297,600 shares.
Earlier in the day, the stock touched an all-time low of $1.30, before recovering some ground.
Zelnecirnon was being evaluated as a treatment for asthma and atopic dermatitis. The trials were placed on clinical hold by the FDA in February because of a serious adverse event of liver injury requiring transplant in one patient in the atopic dermatitis trial, RAPT said.
The biopharmaceutical company said it is continuing to advance the preclinical pipeline, including next-generation CCR4 compounds, and to pursue licensing opportunities.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
November 11, 2024 15:30 ET (20:30 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。